CRMD: CorMedix Inc. Stock

by  •  • Comments Off on CRMD: CorMedix Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 395.65
Enterprise Value ($M) 355.00
Book Value ($M) 84.66
Book Value / Share 1.30
Price / Book 4.67
NCAV ($M) 80.39
NCAV / Share 1.23
Price / NCAV 4.92

Profitability (mra)
Return on Invested Capital (ROIC) -0.21
Return on Assets (ROA) -0.26
Return on Equity (ROE) -0.31

Liquidity (mrq)
Quick Ratio 3.16
Current Ratio 3.39

Balance Sheet (mrq) ($M)
Current Assets 114.58
Assets 118.85
Liabilities 34.19
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 43.47
Operating Income -22.36
Net Income -17.93
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -50.61
Cash from Investing 21.23
Cash from Financing 26.32

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-05 13G/A BlackRock, Inc. 7.50 30.23
11-14 13G/A Nomura Holdings Inc 0.30 -94.25

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTIO
2024-10-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-02 360,535 1,022,729 35.25
2025-04-01 316,197 1,044,478 30.27
2025-03-31 438,408 1,757,715 24.94
2025-03-28 601,935 1,902,523 31.64

(click for more detail)

Similar Companies
CLSD – Clearside Biomedical, Inc. CLYM – Climb Bio, Inc.
CMRX – Chimerix, Inc. CRON – Cronos Group Inc.
CRSP – CRISPR Therapeutics AG


Financial data and stock pages provided by
Fintel.io

Finpedia: CorMedix